ConductScience.org, home

Paper29517954

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.

Brahmer JR and 2 others. J Oncol Pract, 2018. Cited by 351 papers, by iCite.

Cite this record

ConductScience Library. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. Papers, record 29517954. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29517954

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
PubMed
Journal
J Oncol Pract
PubMed
Year
2018
PubMed
Publication types
Journal Article, Practice Guideline
PubMed
Citations, by iCite
351
iCite
Relative citation ratio, by iCite
12.3
iCite
Revised in PubMed
2019-06-24
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Brahmer JRJulie R
2Lacchetti CChristina
3Thompson JAJohn A

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, ImmunologicalMajor topic
Drug-Related Side Effects and Adverse ReactionsMajor topic
Molecular Targeted TherapyMajor topic
NeoplasmsMajor topic
Biomarkers, Tumor
Disease Management
Humans

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04062708CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung CancerBackgroundClinicalTrials.gov
NCT05867004Blocking TNF to Potentiate the ICI-dependent Immune Awakening in MelanomaBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in30020818Reply to D.L. Kimpel et al.https://conductscience.org/library/papers/30020818PubMed
Comment in30020819Collaboration Between Rheumatology and Oncology in Immune Checkpoint Inhibitor Therapy.https://conductscience.org/library/papers/30020819PubMed

Download CSV of comments and corrections

Cited by257

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 351 citations.

PMIDTitleJournalYearIn PapersSource
42958364Immune checkpoints: cross-disease insights and clinical dilemmas.Biomark Res2026https://conductscience.org/library/papers/42958364PubMed
42831226Differentiating Persistent Sepsis From Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis and Concurrent Immune-Mediated Nephritis: A Diagnostic and Therapeutic Challenge.Cureus2026https://conductscience.org/library/papers/42831226PubMed
42820064The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.J Immunother Precis Oncol2026https://conductscience.org/library/papers/42820064PubMed
42763605Quality Assessment of an Immunotherapy Toxicity Clinic: A Clinical Audit at Castle Hill Hospital Evaluating Adherence to Clinical Guidelines, Documentation Standards, and Clinical Outcomes.Cureus2026https://conductscience.org/library/papers/42763605PubMed
42633201Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab.Cureus2026https://conductscience.org/library/papers/42633201PubMed
42534193Aseptic Meningitis With Multiple Cranial Nerve Symptoms Induced by Atezolizumab for Lung Adenocarcinoma: A Case Report.Cureus2026https://conductscience.org/library/papers/42534193PubMed
42524550The Real-World Safety Profile of Immune Checkpoint Inhibitors in Melanoma: FAERS Pharmacovigilance Analysis Complemented by Randomized Trial Evidence.Health Sci Rep2026https://conductscience.org/library/papers/42524550PubMed
42491088Evolution of clinical benefit in cancer trials: comparing pivotal approval data with updated efficacy.Front Public Health2026https://conductscience.org/library/papers/42491088PubMed
42483135Cytomegalovirus (CMV) Co-infection in Treatment-Refractory Immune Checkpoint Inhibitor-Associated Colitis: A Case Report.Cureus2026https://conductscience.org/library/papers/42483135PubMed
42460315Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42460315PubMed
42426360Efficacy of checkpoint inhibitors in genitourinary cancers with advanced chronic kidney disease.Cancer Immunol Immunother2026https://conductscience.org/library/papers/42426360PubMed
42360103Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.J Enzyme Inhib Med Chem2026https://conductscience.org/library/papers/42360103PubMed
42292465Severe immune checkpoint inhibitor-induced 3M syndrome: a case report.Front Immunol2026https://conductscience.org/library/papers/42292465PubMed
42189338Cancer immunotherapy: mechanisms, clinical applications, resistance and future directions.Mol Biol Rep2026https://conductscience.org/library/papers/42189338PubMed
42181373Myositis-Myasthenia Overlap Syndrome After Immune Checkpoint Inhibitor Treatment: A Case Report.Cureus2026https://conductscience.org/library/papers/42181373PubMed
42134550Prospective serial cardiovascular magnetic resonance imaging of immune checkpoint inhibitor myocarditis correlates with cardiovascular outcomes.J Cardiovasc Magn Reson2026https://conductscience.org/library/papers/42134550PubMed
42122148PD-L1-Guided Chemo-Immunotherapy in Advanced Triple-Negative Breast Cancer: A Meta-Analysis of Survival Benefits and Toxicity Profiles.Cancers (Basel)2026https://conductscience.org/library/papers/42122148PubMed
42099345When Immunotherapy Hits the Joints: A Case of Late-Onset Polyarthritis Induced by an Immune Checkpoint Blockade and Literature Review.Cureus2026https://conductscience.org/library/papers/42099345PubMed
42037888Gastrointestinal Toxicities of Targeted Cancer Therapies: A Narrative Review.Cureus2026https://conductscience.org/library/papers/42037888PubMed
41959988A Persistent Pneumonia or an Uncommon Condition: A Case of Immunotherapy-Induced Pneumonitis.Cureus2026https://conductscience.org/library/papers/41959988PubMed

See all 257 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29517954

GET https://conductscience.org/api/papers/v1/29517954/cited_by?page=2